Aging is characterized by chronic low-grade inflammation—a state commonly dismissed as a breakdown of inflammatory regulation. I see it differently. Inflammaging may represent an epigenetic checkpoint that traps cells in a senescent-inflammatory phenotype rather than a failure of inflammatory signaling itself. My hypothesis centers on UHRF1, a protein that accumulates in aging tissues and maintains DNA methylation patterns that silence genes required for proper regenerative responses to inflammatory cytokines. This causes cells to execute only the inflammatory arm of what should be a bifurcated developmental program, while being unable to complete the repair or regeneration arm. Berberine triggers proteasomal degradation of UHRF1 [1], effectively unlocking this epigenetic checkpoint. This permits cells to execute quiescence and tissue maintenance programs correctly instead of becoming permanently stuck in senescence.

The core idea here is that inflammation isn't aging's symptom—it's the body's attempt to restart a program that won't compile. This maps directly onto UHRF1's role as an epigenetic keeper. UHRF1 coordinates DNA methylation maintenance and histone modifications, effectively locking cells into specific transcriptional states [1]. During aging, accumulated UHRF1 may create a methylation landscape that prevents response to regenerative signals. Even when inflammatory cytokines properly signal for tissue repair, the epigenetic machinery blocks execution of downstream regenerative genes. This would explain why inflammaging appears as a repeated retry loop: the signals are correct, but the cellular hardware cannot compile the program.

Berberine's demonstrated suppression of gero-conversion [2] likely occurs because UHRF1 degradation removes this epigenetic blockade. Cells in cell cycle arrest could then re-enter proper quiescence or execute repair programs rather than transitioning to full senescence. The dual action of AMPK activation enhancing autophagy [3] while UHRF1 depletion permits epigenetic reprogramming suggests berberine simultaneously provides metabolic energy and removes the epigenetic constraint for proper program execution.

This framework leads to several testable predictions:

First, an epigenetic locking assay would examine whether aged fibroblasts or stem cells show increased UHRF1 occupancy at promoters of regenerative genes (YAP/TAZ targets, wound healing genes) compared to young cells, with corresponding DNA hypermethylation and transcriptional silencing—even when stimulated with inflammatory cytokines known to induce regenerative responses in young cells.

Second, a rescue experiment could test whether knockdown of UHRF1 in aged cells recapitulates berberine's effects: restored regenerative gene expression in response to inflammatory signals, reduced senescence-associated β-galactosidase, and decreased proinflammatory cytokine secretion without compromising acute inflammatory responses.

Third, in vivo correlation studies could examine whether mouse tissues with high UHRF1 expression during aging show impaired regenerative capacity (delayed wound healing, reduced stem cell function) despite elevated inflammatory markers—supporting the concept of blocked rather than failed signaling.

Finally, falsification would occur if UHRF1 knockdown fails to restore regenerative responses or if aged cells without elevated UHRF1 still exhibit inflammaging, indicating inflammation causes epigenetic locking rather than the reverse.

This hypothesis synthesizes berberine's multiple mechanisms—AMPK activation, UHRF1 degradation, autophagy enhancement—into a unified framework. The compound may work not by suppressing inflammation, but by removing the epigenetic barrier that prevents cells from responding to inflammation's call for repair.